194 related articles for article (PubMed ID: 36303126)
1. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
2. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
3. Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.
Liang JH; Wang WT; Du KX; Xing TY; Wang Y; Wang H; Liu L; Guo R; Shao Y; Liang J; Li Y; Shen HR; Wang L; Li JY; Xu W
Hum Cell; 2023 Mar; 36(2):835-846. PubMed ID: 36520345
[TBL] [Abstract][Full Text] [Related]
4. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.
Huo J; Fu L; Jin M; Li Z; Zhang M
Invest New Drugs; 2022 Jun; 40(3):537-545. PubMed ID: 35226228
[TBL] [Abstract][Full Text] [Related]
5. ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.
Zhang X; Zhao L; Li X; Wang X; Li L; Fu X; Sun Z; Li Z; Nan F; Chang Y; Zhang M
Leuk Res; 2015 Dec; 39(12):1448-54. PubMed ID: 26499190
[TBL] [Abstract][Full Text] [Related]
6. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
Hayes GM; Carrigan PE; Beck AM; Miller LJ
Cancer Res; 2006 Apr; 66(7):3819-27. PubMed ID: 16585209
[TBL] [Abstract][Full Text] [Related]
7. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
8. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma.
Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
[TBL] [Abstract][Full Text] [Related]
9. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma.
Liu H; Liu M; Tian X; Wang H; Gao J; Li H; Zhao Z; Liu Y; Liu C; Chen X; Yang Y
Elife; 2023 Oct; 12():. PubMed ID: 37888961
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
14. m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
Ma H; Shen L; Yang H; Gong H; Du X; Li J
IUBMB Life; 2021 Jan; 73(1):108-117. PubMed ID: 33205540
[TBL] [Abstract][Full Text] [Related]
15. Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and SOCS1.
Zhang YH; Tao Q; Zhang WY; Zhao S; Liu WP; Gao LM
Genes Genomics; 2024 Feb; 46(2):203-212. PubMed ID: 37523130
[TBL] [Abstract][Full Text] [Related]
16. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells.
Wang C; Zhou Z; Subhramanyam CS; Cao Q; Heng ZSL; Liu W; Fu X; Hu Q
Commun Biol; 2020 May; 3(1):268. PubMed ID: 32461560
[TBL] [Abstract][Full Text] [Related]
17. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
18. EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma.
Lee JY; Kim JH; Bang H; Cho J; Ko YH; Kim SJ; Kim WS
Sci Rep; 2021 May; 11(1):10342. PubMed ID: 33990633
[TBL] [Abstract][Full Text] [Related]
19. Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.
Lin JC; Lin CY; Tarn WY; Li FY
RNA; 2014 Oct; 20(10):1621-31. PubMed ID: 25140042
[TBL] [Abstract][Full Text] [Related]
20. [Bortezomib Inhibits Extranodal Natural Killer/T Cell Lymphoma, Nasal Type by Targeting NF-κB Signaling Pathway].
Li JH; Zhang L; Feng Y; Zou LQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):311-316. PubMed ID: 31631595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
